HIGHLIGHTS
- who: Niek A. Peters from the Hospital in Halle, Germany have published the Article: Consensus molecular subtype 4 (CMS4)-targeted therapy in primary colon cancer: A proof-of-concept study, in the Journal: (JOURNAL)
- what: Identification of imatinib as a candidate CMS4-targeting drug To search for potential therapeutic targets in CMS4 CRC the authors focused on the human kinome. This study shows the feasibility of mitigating the aggressive biology of CMS4 primary colon cancer with targeted therapy in pre-selected cancer patients. The authors have provided proof-of-concept that the aggressive phenotype of . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.